Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Study sponsor: Exelixis
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-01-31Actual
Enrollment · participants855Actual
Source updated2026-10-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.